Grail, Inc. february 23, 2026 Please complete the form below to contact Kaplan Fox regarding the Grail Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Jeffrey P. Campisi JCampisi@kaplanfox.comLaurence D. KingLKing@kaplanfox.com GRAL ALERT: Kaplan Fox is Investigating Grail, Inc. (NASDAQ: GRAL) for Potential Securities Law Violations Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grail, Inc. (“Grail” or the “Company”) (Nasdaq: GRAL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THE GRAIL INVESTIGATION If you are a Grail investor and have suffered losses, or if you have information that could assist in the Grail investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (646) 315-9003. On February 19, 2026, after the close of trading, Grail issued a press release titled “GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results” that announced “topline results from the landmark, randomized, controlled NHS-Galleri trial, which evaluated annual screening with the Galleri® test in England’s National Health Service (NHS) over three years in 142,000 demographically representative participants aged 50 to 77. The results show that adding Galleri to standard of care screening resulted in a substantial reduction in Stage IV cancer diagnoses, increased Stage I and II detection of deadly cancers, and four-fold higher cancer detection rate when compared to standard of care alone. While there was a trend towards reduction in combined Stage III and IV, the trial did not meet the primary endpoint of a statistically significant reduction.” Following this news, the price of Grail stock fell $51.32 per share, or 50.55%, to close at $50.21 per share on February 20, 2026. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this investigation, please contact: CONTACT KAPLAN FOX: Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(212) 329-8571jcampisi@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1501Oakland, California 94612(415) 772-4704lking@kaplanfox.com Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Grail, Inc. Shareholder Alert: Learn More Now See the Case Kyndryl Holdings, Inc. See the Case Hub Group, Inc. See the Case Ralliant Corporation See the Case Beyond Meat, Inc. See the Case BlackRock TCP Capital Corp. See the Case Commvault Systems, Inc. See the Case REGENXBIO Inc. See the Case Navan, Inc. See the Case Nutanix, Inc. See the Case Lakeland Industries, Inc. See the Case BellRing Brands, Inc. See the Case
